Anti-EGFR monoclonal antibody Cetuximab displays potential anti-cancer activities in feline oral squamous cell carcinoma cell lines
暂无分享,去创建一个
[1] C. Borel,et al. The EXTREME Regimen Associating Cetuximab and Cisplatin Favors Head and Neck Cancer Cell Death and Immunogenicity with the Induction of an Anti-Cancer Immune Response , 2022, Cells.
[2] P. Hegyi,et al. Addition of EGFR inhibitors to standard chemotherapy increases survival of advanced head and neck squamous cell carcinoma patients: a systematic review and meta-analysis. , 2022, Oral diseases.
[3] S. Brandt,et al. Investigation of multiple Felis catus papillomavirus types (-1/-2/-3/-4/-5/-6) DNAs in feline oral squamous cell carcinoma: a multicentric study , 2022, The Journal of veterinary medical science.
[4] D. Tenen,et al. EGFR signaling pathway as therapeutic target in human cancers. , 2022, Seminars in cancer biology.
[5] R. Milner,et al. Identification of the interleukin-8 (CXCL-8) pathway in feline oral squamous cell carcinoma - A pilot study. , 2022, Canadian journal of veterinary research = Revue canadienne de recherche veterinaire.
[6] N. Lee,et al. HPV‐associated oropharyngeal cancer de‐escalation strategies and trials: Past failures and future promise , 2021, Journal of surgical oncology.
[7] Young-Kyun Kim,et al. Cisplatin Plus Cetuximab Inhibits Cisplatin-Resistant Human Oral Squamous Cell Carcinoma Cell Migration and Proliferation but Does Not Enhance Apoptosis , 2021, International journal of molecular sciences.
[8] G. de Luca,et al. The Small Molecule BIBR1532 Exerts Potential Anti-cancer Activities in Preclinical Models of Feline Oral Squamous Cell Carcinoma Through Inhibition of Telomerase Activity and Down-Regulation of TERT , 2021, Frontiers in Veterinary Science.
[9] W. Weichert,et al. Adaptive ERK signalling activation in response to therapy and in silico prognostic evaluation of EGFR-MAPK in HNSCC , 2020, British Journal of Cancer.
[10] W. Xia,et al. TLR4 activation leads to anti-EGFR therapy resistance in head and neck squamous cell carcinoma. , 2020, American journal of cancer research.
[11] C. Eleni,et al. Detection of Felis catus papillomavirus type-2 DNA and viral gene expression suggest active infection in feline oral squamous cell carcinoma. , 2020, Veterinary and comparative oncology.
[12] M. Kiupel,et al. Immunohistochemical Features of Epithelial-Mesenchymal Transition in Feline Oral Squamous Cell Carcinoma , 2019, Veterinary pathology.
[13] Priya Londhe,et al. Targeted Therapies in Veterinary Oncology. , 2019, The Veterinary clinics of North America. Small animal practice.
[14] G. Altamura,et al. HPV related head and neck squamous cell carcinoma: New evidences for an emerging spontaneous animal model. , 2019, Oral oncology.
[15] G. de Luca,et al. Felis catus papillomavirus type-2 E6 binds to E6AP, promotes E6AP/p53 binding and enhances p53 proteasomal degradation , 2018, Scientific Reports.
[16] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[17] R. Concu,et al. Cetuximab and the Head and Neck Squamous Cell Cancer. , 2018, Current topics in medicinal chemistry.
[18] D. Argyle,et al. Dual targeting of EGFR and ERBB2 pathways produces a synergistic effect on cancer cell proliferation and migration in vitro , 2017, Veterinary and comparative oncology.
[19] D. Smolensky,et al. Inhibition of the PI3K/AKT Pathway Sensitizes Oral Squamous Cell Carcinoma Cells to Anthracycline‐Based Chemotherapy In Vitro , 2017, Journal of cellular biochemistry.
[20] T. Hupp,et al. Challenges and opportunities for monoclonal antibody therapy in veterinary oncology. , 2016, Veterinary journal.
[21] S. LaRue,et al. Predicting clinical outcome in feline oral squamous cell carcinoma: tumour initiating cells, telomeres and telomerase. , 2016, Veterinary and comparative oncology.
[22] A. Corteggio,et al. Felis catus papillomavirus type 2 E6 oncogene enhances mitogen-activated protein kinases and Akt activation but not EGFR expression in an in vitro feline model of viral pathogenesis. , 2016, Veterinary microbiology.
[23] Shijie Cao,et al. Combined oridonin with cetuximab treatment shows synergistic anticancer effects on laryngeal squamous cell carcinoma: involvement of inhibition of EGFR and activation of reactive oxygen species-mediated JNK pathway. , 2016, International journal of oncology.
[24] Melissa D. Sánchez,et al. Feline Oral Squamous Cell Carcinoma: Clinical Manifestations and Literature Review , 2015, Journal of veterinary dentistry.
[25] G. Piontek,et al. The response of head and neck squamous cell carcinoma to cetuximab treatment depends on Aurora kinase A polymorphism , 2014, Oncotarget.
[26] T. Stockner,et al. Generation of a Canine Anti-EGFR (ErbB-1) Antibody for Passive Immunotherapy in Dog Cancer Patients , 2014, Molecular Cancer Therapeutics.
[27] J. Wypij. A Naturally Occurring Feline Model of Head and Neck Squamous Cell Carcinoma , 2013, Pathology research international.
[28] L. Nasir,et al. Analysis of Activated Platelet-Derived Growth Factor β Receptor and Ras-MAP Kinase Pathway in Equine Sarcoid Fibroblasts , 2013, BioMed research international.
[29] D. Thamm,et al. Immunohistochemical characterization of feline oral squamous cell carcinoma. , 2012, American journal of veterinary research.
[30] H. Allgayer,et al. Cetuximab and biomarkers in non-small-cell lung carcinoma , 2012, Biologics : targets & therapy.
[31] T. Rosol,et al. Characterization of bone resorption in novel in vitro and in vivo models of oral squamous cell carcinoma. , 2012, Oral oncology.
[32] T. Stockner,et al. Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting , 2012, Molecular immunology.
[33] L. Dušek,et al. Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas. , 2012, Neoplasma.
[34] L. Pang,et al. Studies on the inhibition of feline EGFR in squamous cell carcinoma: Enhancement of radiosensitivity and rescue of resistance to small molecule inhibitors , 2011, Cancer biology & therapy.
[35] P. Peixoto,et al. Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in bypassing this resistance. , 2010, International journal of oncology.
[36] T. Rosol,et al. Zoledronic acid reduces bone loss and tumor growth in an orthotopic xenograft model of osteolytic oral squamous cell carcinoma. , 2010, Cancer research.
[37] T. Rosol,et al. Feline head and neck squamous cell carcinoma cell line: Characterization, production of parathyroid hormone-related protein, and regulation by transforming growth factor-β , 2001, In Vitro Cellular & Developmental Biology - Animal.
[38] R. Rosell,et al. Epidermal Growth Factor Receptor Activation: How Exon 19 and 21 Mutations Changed Our Understanding of the Pathway , 2006, Clinical Cancer Research.
[39] Zhimin Lu,et al. ERK1/2 MAP kinases in cell survival and apoptosis , 2006, IUBMB life.
[40] P. Jeffrey,et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. , 2005, Cancer cell.
[41] J. Baselga. The EGFR as a target for anticancer therapy--focus on cetuximab. , 2001, European journal of cancer.
[42] N. Holbrook,et al. Requirement for ERK Activation in Cisplatin-induced Apoptosis* , 2000, The Journal of Biological Chemistry.